Using the genetic concept of synthetic lethality [3, 4], PARP inhibitors are designed to target cancers harbouring specific DNA-repair defects, including those arising in carriers of BRCA1 or BRCA2 mutations [5]. Here, BRCA1 is linked to cancer.